Lyell Immunopharma Files 8-K Report
Ticker: LYEL · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Lyell Immunopharma filed an 8-K on 6/17/25 for 'Other Events' - details pending.
AI Summary
On June 17, 2025, Lyell Immunopharma, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding transactions, agreements, or financial figures were provided in the excerpt.
Why It Matters
This filing signals a material event for Lyell Immunopharma, Inc., requiring disclosure to investors and the public. The nature of the 'Other Events' will determine the specific impact.
Risk Assessment
Risk Level: medium — The risk level is medium because an 8-K filing indicates a significant event, but the lack of detail in the provided excerpt makes it impossible to assess the precise nature or magnitude of the risk.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Lyell Immunopharma, Inc. in this 8-K filing?
The provided excerpt does not specify the details of the 'Other Events'.
When was this 8-K report filed by Lyell Immunopharma, Inc.?
The report was filed on June 17, 2025.
What is the principal executive office address for Lyell Immunopharma, Inc.?
The principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Lyell Immunopharma, Inc.'s state of incorporation?
Lyell Immunopharma, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Lyell Immunopharma, Inc. (LYEL).